its cost of capital to be 12% for the purpose of its performance evaluations
Balance Sheet |
Income Statement |
|
£’000 |
£’000 |
|
Non-current assets |
1,500 |
Revenue 4,000 |
Current assets |
600 |
Operating costs 3,600 |
2,100 |
Operating profit 400 |
|
Divisional equity |
1,000 |
Interest paid 70 |
Long-term borrowings |
700 |
Profit before tax 330 |
Current liabilities |
400 |
|
2,100 |
For many years prior to the year ended March 2019 the annual expenditure on research and development was £200,000. Due to the launch of a new product, in the year ended March 2019 the amount was increased to £300,000. New products are expected to last four years.
For EVA calculations assume that research and development costs start to be charged in the year the investment takes place, and the EVA book value of past research and development costs was £300,000 at the beginning of 2018-19.
What is the correct Economic Value Added (EVA) for Tetra Division for the year ended 31 March 2019?
Statement of Economic value-added
Particulars | Amt(000) | |
Economic profit | (a) | 500 |
WACC | (b) | 11.18% |
Economic capital employed | (c) | 2,000 |
EVA = a-(b*c) | ||
=500 - (11.18%*2,000) | 27.64 |
a) Economic profit
Operating profit = 400
Add Research and development = 100
Economic profit 500
b) WACC
Equity | 1,000 | 12% | 120 |
Long term borrowings | 700 | 10% | 70 |
Total | 1,700 | 190 |
WACC = 190/1700 =11.18%
c) Economic capital employed
Divisional equity | 1,000 |
Long-term borrowings | 700 |
Research and Development Expenditure | 300 |
Total | 2,000 |
Get Answers For Free
Most questions answered within 1 hours.